Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perfluorohexyloctane Eye Drops for MGD-Associated Dry Eye in Type 2 Diabetes
ChiCTR2500115660Phase 4Not yet recruiting
- Sponsor
- Qingdao Eye Hospital of Shandong First Medical University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of perfluorohexyloctane in dry eye syndrome (DED), meibomian gland dysfunction (MGD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Qingdao Eye Hospital of Shandong First Medical University. Primary endpoint: Ocular Surface Disease Index score. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
perfluorohexyloctane
03
Conditions
dry eye syndrome (DED)meibomian gland dysfunction (MGD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500115660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115660.